CCL

Összesen 5 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM077367
035-os BibID:(WoS)000423233400006 (Scopus)85041389324
Első szerző:Connors, Joseph M.
Cím:Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma / J. M. Connors, W. Jurczak, D. J. Straus, S. M. Ansell, W. S. Kim, A. Gallamini, A. Younes, S. Alekseev, Á. Illés, M. Picardi, E. Lech-Maranda, Y. Oki, T. Feldman, P. Smolewski, K. J. Savage, N. L. Bartlett, J. Walewski, R. Chen, R. Ramchandren, P. L. Zinzani, D. Cunningham, A. Rosta, N. C. Josephson, E. Song, J. Sachs, R. Liu, H. A. Jolin, D. Huebner, J. Radford, ECHELON-1 Study Group
Dátum:2018
ISSN:0028-4793
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:New England Journal of Medicine. - 378 : 9 (2018), p. 331-344. -
További szerzők:Jurczak, Wojciech Straus, David J. Ansell, Stephen M. Kim, Won Seog Gallamini, Andrea Younes, Anas Alekseev, Sergey Illés Árpád (1959-) (belgyógyász, haematológus, onkológus) Picardi, Marco Lech-Maranda, Ewa Oki, Yasuhiro Feldman, Tatyana Smolewski, Piotr Savage, Kerry J. Bartlett, Nancy L. Walewski, Jan Chen, Robert Ramchandren, Radhakrishnan Zinzani, Pier Luigi Cunningham, David Rosta András Josephson, Neil C. Song, Eric Sachs, Jessica Liu, Rachael Jolin, Hina A. Huebner, Dirk Radford, John ECHELON-1 Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM120740
035-os BibID:(Scopus)85122922204 (WOS)000755659500008
Első szerző:Horwitz, Steven
Cím:The ECHELON-2 Trial : 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma / S. Horwitz, O. A. O`Connor, B. Pro, L. Trümper, S. Iyer, R. Advani, N. L. Bartlett, J. H. Christensen, F. Morschhauser, E. Domingo-Domenech, G. Rossi, W. S. Kim, T. Feldman, T. Menne, D. Belada, Á. Illés, K. Tobinai, K. Tsukasaki, S.-P. Yeh, A. Shustov, A. Hüttmann, K. J. Savage, S. Yuen, P. L. Zinzani, H. Miao, V. Bunn, K. Fenton, M. Fanale, M. Puhlmann, T. Illidge
Dátum:2022
ISSN:0923-7534 1569-8041
Megjegyzések:Background: For patients with peripheral T-cell lymphoma (PTCL), outcomes using frontline treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like therapy are typically poor. The ECHELON-2 study demonstrated that brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (A CHP) exhibited statistically superior progression-free survival (PFS) per independent central review and improvements in overall survival versus CHOP for the frontline treatment of patients with systemic anaplastic large cell lymphoma or other CD30-positive PTCL. Patients and methods: ECHELON-2 is a double-blind, double-dummy, randomized, placebo-controlled, active-comparator phase III study. We present an exploratory update of the ECHELON-2 study, including an analysis of 5-year PFS per investigator in the intent-to-treat analysis group. Results: A total of 452 patients were randomized (1 : 1) to six or eight cycles of A+CHP (N = 226) or CHOP (N = 226). At median follow-up of 47.6 months, 5-year PFS rates were 51.4% [95% confidence interval (CI): 42.8% to 59.4%] with A+CHP versus 43.0% (95% CI: 35.8% to 50.0%) with CHOP (hazard ratio = 0.70; 95% CI: 0.53-0.91), and 5-year overall survival (OS) rates were 70.1% (95% CI: 63.3% to 75.9%) with A+CHP versus 61.0% (95% CI: 54.0% to 67.3%) with CHOP (hazard ratio = 0.72; 95% CI: 0.53-0.99). Both PFS and OS were generally consistent across key subgroups. Peripheral neuropathy was resolved or improved in 72% (84/117) of patients in the A+CHP arm and 78% (97/124) in the CHOP arm. Among patients who relapsed and subsequently received brentuximab vedotin, the objective response rate was 59% with brentuximab vedotin retreatment after A+CHP and 50% with subsequent brentuximab vedotin after CHOP. Conclusions: In this 5-year update of ECHELON-2, frontline treatment of patients with PTCL with A+CHP continues to provide clinically meaningful improvement in PFS and OS versus CHOP, with a manageable safety profile, including continued resolution or improvement of peripheral neuropathy.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
brentuximab vedotin
CHOP
frontline treatment
overall survival
peripheral T-cell lymphoma
randomized clinical trial
Megjelenés:Annals Of Oncology. - 33 : 3 (2022), p. 288-298. -
További szerzők:O'Connor, Owen A. Pro, B. Trümper, Lorenz Iyer, Swaminathan Advani, Ranjana Bartlett, Nancy L. Christensen, Jacob Haaber Morschhauser, Franck Domingo-Domenech, Eva Rossi, Giuseppe Kim, Won-Seok Feldman, Tatyana Menne, T. Belada, David Illés Árpád (1959-) (belgyógyász, haematológus, onkológus) Tobinai, Kensei Tsukasaki, Kunihiro Yeh, Su-Peng Shustov, Andrei Hüttmann, Andreas Savage, Kerry J. Yuen, Sam Zinzani, Pier Luigi Miao, Harry Bunn, V. Fenton, Keenan Fanale, Michelle Puhlmann, M. Illidge, Tim
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM077363
035-os BibID:(WoS)000456000000026 (Scopus)85059506213
Első szerző:Horwitz, Steven
Cím:Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2) : a global, double-blind, randomised, phase 3 trial / Steven Horwitz, Owen A. O'Connor, Tim Illidge, Michelle Fanale, Ranjana Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Franck Morschhauser, Eva Domingo-Domenech, Giuseppe Rossi, Won Seog Kim, Tatyana Feldman, Anne Lennard, David Belada, Árpád Illés, Kensei Tobinai, Kunihiro Tsukasaki, Su-Peng Yeh, Andrei Shustov, Andreas Hüttmann, Kerry J. Savage, Sam Yuen, Swaminathan Iyer, Pier Luigi Zinzani, Zhaowei Hua, Meredith Little, Shangbang Rao, Joseph Woolery, Thomas Manley, Lorenz Trümper, ECHELON-2 Study Group
Dátum:2019
ISSN:2352-3026
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:The Lancet Haematology. - 393 : 10168 (2019), p. 229-240. -
További szerzők:O'Connor, Owen A. Illidge, Tim Fanale, Michelle Advani, Ranjana Bartlett, Nancy L. Christensen, Jacob Haaber Morschhauser, Franck Domingo-Domenech, Eva Rossi, Giuseppe Kim, Won Seog Feldman, Tatyana Lennard, Anne Belada, David Illés Árpád (1959-) (belgyógyász, haematológus, onkológus) Tobinai, Kensei Tsukasaki, Kunihiro Yeh, Su-Peng Shustov, Andrei Hüttmann, Andreas Savage, Kerry J. Yuen, Sam Iyer, Swaminathan Zinzani, Pier Luigi Hua, Zhaowei Little, Meredith Rao, Shangbang Woolery, Joseph Manley, Thomas Trümper, Lorenz ECHELON-2 Study Group
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

4.

001-es BibID:BIBFORM100470
Első szerző:Straus, David J.
Cím:Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1) : 5-year update of an international, open-label, randomised, phase 3 trial / Straus David J., Dugosz-Danecka Monika, Connors Joseph M., Alekseev Sergey, Illés Árpád, Picardi Marco, Lech-Maranda Ewa, Feldman Tatyana, Smolewski Piotr, Savage Kerry J., Bartlett Nancy L., Walewski Jan, Ramchandren Radhakrishnan, Zinzani Pier Luigi, Hutchings Martin, Munoz Javier, Lee Hun Ju, Kim Won Seog, Advani Ranjana, Ansell Stephen M., Younes Anas, Gallamini Andrea, Liu Rachael, Little Meredith, Fenton Keenan, Fanale Michelle, Radford John
Dátum:2021
ISSN:2352-3026
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:The Lancet Haematology. - 8 : 6 (2021), p. e410-e421. -
További szerzők:Dugosz-Danecka, Monika Connors, Joseph M. Alekseev, Sergey Illés Árpád (1959-) (belgyógyász, haematológus, onkológus) Picardi, Marco Lech-Maranda, Ewa Feldman, Tatyana Smolewski, Piotr Savage, Kerry J. Bartlett, Nancy L. Walewski, Jan Ramchandren, Radhakrishnan Zinzani, Pier Luigi Hutchings, Martin Munoz, Javier Lee, Hun Ju Kim, Won Seog Advani, Ranjana Ansell, Stephen M. Younes, Anas Gallamini, Andrea Liu, Rachael Little, Meredith Fenton, Keenan Fanale, Michelle Radford, John
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM083082
035-os BibID:(PMID)31945149 (WoS)000523314100008 (Scopus)85081944235
Első szerző:Straus, David J.
Cím:Brentuximab vedotin with chemotherapy for Stage III/IV classical Hodgkin lymphoma : 3-year update of the ECHELON-1 study / David J. Straus, Monika Długosz-Danecka, Sergiy Alekseev, Árpád Illés, Marco Picardi, Ewa Lech-Maranda, Tatyana Feldman, Piotr Smolewski, Kerry J. Savage, Nancy L. Bartlett, Jan Walewski, Radhakrsihnan Ramchandren, Pier Luigi Zinzani, Martin Hutchings, Joseph M. Connors, John Radford, Javier Munoz, Won Seog Kim, Ranjana Advani, Stephen Ansell, Anas Younes, Harry Miao, Rachael Liu, Keenan Fenton, Andres Forero-Torres, Andrea Gallamini
Dátum:2020
Megjegyzések:The phase 3 ECHELON-1 study demonstrated that brentuximab vedotin (A) with AVD (A+AVD) exhibited superior modified PFS versus ABVD for the frontline treatment of patients with stage III/IV classical Hodgkin lymphoma (cHL) (NCT01712490; 2011-005450-60). Maturing data from positron emission tomography (PET)-adapted trials highlight potential limitations of PET-adapted approaches, including toxicities with dose intensification and higher-than-expected relapse rates in PET2(-) patients. We present here an update of the ECHELON-1 study, including an exploratory analysis of 3-year PFS per investigator. 1334 patients with stage III or IV cHL were randomized 1:1 to receive six cycles of A+AVD (n = 664) or ABVD (n = 670). Interim PET scan after cycle 2 (PET2) was required. At a median follow-up of 37 months, 3-year PFS rates were 83.1% with A+AVD and 76.0% with ABVD; 3-year PFS rates in PET2(-) patients aged <60 years were 87.2% versus 81.0%, respectively. A beneficial trend in PET2(+) patients aged <60 years on A+AVD was also observed, with a 3-year PFS rate of 69.2% versus 54.7% with ABVD. The benefit of A+AVD in the intent-to-treat population appeared independent of disease stage and prognostic risk factors. Upon continued follow-up, 78% of patients with peripheral neuropathy (PN) on A+AVD had either complete resolution or improvement compared with 83% on ABVD. These data highlight that A+AVD provides a durable efficacy benefit compared with ABVD for frontline stage III/IV cHL which is consistent across key subgroups regardless of patient status at PET2, without need for treatment intensification or exposure to bleomycin.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Blood. - 135 : 10 (2020), p. 735-742. -
További szerzők:Długosz-Danecka, Monika Alekseev, Sergey Illés Árpád (1959-) (belgyógyász, haematológus, onkológus) Picardi, Marco Lech-Maranda, Ewa Feldman, Tatyana Smolewski, Piotr Savage, Kerry J. Bartlett, Nancy L. Walewski, Jan Ramchandren, Radhakrishnan Zinzani, Pier Luigi Hutchings, Martin Connors, Joseph M. Radford, John Munoz, Javier Kim, Won Seog Advani, Ranjana Ansell, Stephen M. Younes, Anas Miao, Harry Liu, Rachael Fenton, Keenan Forero-Torres, Andres Gallamini, Andrea
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v10.1.21-SNAPSHOT © 2024 Monguz kft. Minden jog fenntartva.